Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMKC8F9)

• Drug Name: 4SCAR19 and 4SCAR70 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
B-cell lymphoma	2A86	Phase 1/2	[1]

• Cross-matching ID: TTD Drug ID: DMKC8F9

Molecule-Related Drug Atlas

Drug(s) Targeting B-lymphocyte surface antigen B4 (CD19)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tisagenlecleucel	DMM9BJD	Acute lymphoblastic leukaemia	2A85	Approved	[2]
Blinatumomab	DMGECIJ	Acute lymphoblastic leukaemia	2A85	Approved	[3]
Axicabtagene ciloleucel	DMYHN59	Diffuse large B-cell lymphoma	2A81	Approved	[4]
Lisocabtagene maraleucel	DMP45ME	Large B-cell lymphoma	2A81	Approved	[5]
Inebilizumab	DMI0RHA	Neuromyelitis optica spectrum disorder	8E4A.0	Approved	[6]
Tecartus	DMYQCWT	Mantle cell lymphoma	2A85.5	Approved	[7]
Loncastuximab tesirine	DMXSVGI	Diffuse large B-cell lymphoma	2A81	Approved	[8]
Obexelimab	DMVIC4J	IgG4 related disease	4A43.0	Phase 3	[9]
MOR-208	DMDQOWT	Diffuse large B-cell lymphoma	2A81	Phase 2/3	[10]
CART-19	DMST3FM	Acute lymphoblastic leukaemia	2A85	Phase 2/3	[11]

Drug(s) Targeting CD70 antigen (CD27-L)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
JNJ-74494550	DM3ICO6	Myelodysplastic syndrome	2A37	Phase 2	[12]
MDX-1203	DM0RIQF	Solid tumour/cancer	2A00-2F9Z	Phase 1	[13]
MDX-1411	DM3402P	Solid tumour/cancer	2A00-2F9Z	Phase 1	[14]
BMS-936561	DMYIBFM	Haematological malignancy	2B33.Y	Phase 1	[15]
SGN-70	DMXA7W9	Autoimmune diabetes	5A10	Phase 1	[16]
SGN-CD70A	DMMJ1PO	Non-hodgkin lymphoma	2B33.5	Phase 1	[17]
Anti-hCD70 CAR transduced PBL	DMK4GIS	Ovarian cancer	2C73	Phase 1	[18]
AMG 172	DMS72GN	Renal cell carcinoma	2C90	Phase 1	[19]
SEA-CD70	DMX94YF	Acute myeloid leukaemia	2A60	Phase 1	[20]
CTX130	DM926CH	T-cell lymphoma	2A90	Phase 1	[21]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
B-lymphocyte surface antigen B4 (CD19)	TTW640A	CD19_HUMAN	CAR-T-Cell-Therapy(Dual specific)	[1]
CD70 antigen (CD27-L)	TTNCIE0	CD70_HUMAN	CAR-T-Cell-Therapy(Dual specific)	[1]

References

• [1] ClinicalTrials.gov (NCT03125577) Combination CAR-T Cell Therapy Targeting Hematological Malignancies
• [2] 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
• [3] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [4] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services
• [5] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services.
• [6] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [7] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services.
• [8] Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma. Blood. 2021 May 13;137(19):2634-2645.
• [9] Emerging B-Cell Therapies in Systemic Lupus Erythematosus. Ther Clin Risk Manag. 2021 Jan 14;17:39-54.
• [10] A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL. Blood. 2014 Dec 4;124(24):3553-60.
• [11] ClinicalTrials.gov (NCT03027739) CART-19 Cells For MRD Positive CD19+ ALL
• [12] Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents. Nat Med. 2020 Sep;26(9):1459-1467.
• [13] J Clin Oncol 32:5s, 2014 (suppl; abstr 2558).
• [14] Bristol-Myers Squibb swallows last of antibody pioneers. Nat Biotechnol. 2009 Sep;27(9):781-3.
• [15] Pharmacokinetic characterization of BMS-936561, an anti-CD70 antibody-drug conjugate, in preclinical animal species and prediction of its pharmacok... Biopharm Drug Dispos. 2016 Mar;37(2):93-106.
• [16] 2011 Pipeline of Seattle Genetics.
• [17] SGN-CD70A, a novel and highly potent anti-CD70 ADC, induces double-strand DNA breaks and is active in models of MDR+ renal cell carcinoma (RCC) and non-Hodgkin lymphoma (NHL). Cancer Research 10/2014; 74(19 Supplement):2647-2647.
• [18] ClinicalTrials.gov (NCT02830724) Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
• [19] National Cancer Institute Drug Dictionary (drug id 721679).
• [20] Clinical pipeline report, company report or official report of Seagen.
• [21] Clinical pipeline report, company report or official report of CRISPR Therapeutics.